Welcome to our dedicated page for Abbvie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for AbbVie Inc. (NYSE: ABBV), a pharmaceutical preparation manufacturing company focused on immunology, oncology, neuroscience, eye care and its Allergan Aesthetics portfolio. AbbVie’s filings provide structured insight into its financial condition, capital structure, research spending and key corporate events.
Recent Form 8‑K filings discuss items under “Results of Operations and Financial Condition,” including guidance for specific quarters and full‑year periods and the impact of acquired in‑process research and development (IPR&D) and milestones expense on diluted earnings per share. Other 8‑K disclosures describe settlements of litigation related to generic manufacturers of upadacitinib tablets (marketed as RINVOQ) and note that AbbVie’s common stock and multiple series of senior notes are registered and listed on the New York Stock Exchange.
Through this filings feed, users can access AbbVie’s current reports alongside its periodic reports when available, such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q. These documents typically contain details on research and development activities, manufacturing investments, and the performance of key therapeutic areas, as well as discussions of risk factors and capital allocation. For a company active in oncology and other complex therapeutic fields, these filings help explain how collaborations, licensing agreements and acquisitions are reflected in financial statements, particularly through acquired IPR&D and milestones expense.
Stock Titan enhances these filings with AI-powered summaries that highlight important sections, such as earnings guidance updates, litigation disclosures and changes in capital structure. Users can quickly see how items like AbbVie’s guidance revisions, settlement agreements or investment commitments appear in official SEC documents. Real-time updates from EDGAR, combined with AI explanations of forms such as 8‑K and, where applicable, 10‑K, 10‑Q and Form 4 insider transaction reports, allow investors and researchers to review ABBV’s regulatory record more efficiently and understand the context behind headline numbers and corporate announcements.
AbbVie Inc. completed an underwritten public offering of multiple series of senior unsecured notes. The company issued senior floating rate notes due 2028 with an aggregate principal amount of $750,000,000, along with several series of fixed-rate senior notes maturing between 2028 and 2066.
The fixed-rate series include $1,500,000,000 of 3.775% notes due 2028, $1,250,000,000 of 4.125% notes due 2031, $1,250,000,000 of 4.400% notes due 2033, $1,500,000,000 of 4.750% notes due 2036, $1,250,000,000 of 5.550% notes due 2056, and $500,000,000 of 5.650% notes due 2066. All notes rank equally with AbbVie’s other unsecured, unsubordinated obligations.
The notes were issued under an existing shelf registration and an indenture that includes customary covenants, such as limits on certain liens and restrictions on mergers or transfers of substantially all assets. AbbVie has various optional redemption rights, including make-whole redemptions and par calls after specified dates for each longer-dated series.
AbbVie Inc. executive Roopal Thakkar reported a tax-related share disposition. On February 27, 2026, 8,037 shares of AbbVie common stock were disposed of at
AbbVie Inc. director and CEO Michael Robert A. reported a Form 4 transaction involving a tax-related share disposition. On February 27, 2026, he had 36,523 shares of common stock disposed of at $232.08 per share to satisfy tax obligations. After this tax-withholding disposition, he directly owned 178,737 shares of AbbVie common stock.
AbbVie Inc. executive vice president and chief commercial officer Jeffrey Ryan Stewart reported a tax-withholding disposition of 23,812 shares of common stock at
AbbVie Inc. executive Perry C. Siatis, EVP, GC and Secretary, reported several stock transactions. On February 27, 2026, he disposed of 14,850 common shares at
AbbVie Inc. executive vice president and chief financial officer Scott T. Reents reported a tax-related share disposition under a compensation plan. On February 27, 2026, 21,638 shares of AbbVie common stock were disposed of to cover tax withholding obligations. After this transaction, he directly owned 38,777 AbbVie shares.
AbbVie Inc. senior vice president and controller David Ryan Purdue reported a tax-related share disposition. On February 27, 2026, he transferred 2,692 shares of AbbVie common stock at $232.08 per share to cover tax obligations, described as a payment of tax liability by delivering securities.
After this transaction, he directly owned 7,884 shares of AbbVie common stock. He also had an indirect holding of 543 shares through a profit sharing trust, with a footnote noting this balance in an AbbVie savings program as of February 20, 2026, including shares acquired via a dividend reinvestment feature.
AbbVie Inc. executive Azita Saleki‑Gerhardt reported a tax-related share disposition. On February 27, 2026, 16,309 shares of AbbVie common stock were disposed of at
In addition, 2,706 AbbVie shares were held indirectly through a profit sharing trust, reflecting the balance in the AbbVie Savings Program as of
AbbVie Inc. executive Nicholas Donoghoe reported a tax-related share disposition under a compensation plan. On February 27, 2026, he used 12,874 shares of common stock, valued at $232.08 per share, to cover tax withholding. After this transaction, he directly held 74,430 shares of AbbVie common stock.
ABBV insider sale notice: A Form 144 filing lists performance shares to be sold by an issuer-related plan, showing 18,668 units tied to 02/28/2026. The filing also records a prior sale by Perry C. Siatis of 22,381 shares on 02/25/2026 for $5,147,630.00.